期刊文献+

miR-574-5p在乳腺癌患者血清中的水平及与临床病理特征的关系 被引量:5

Relationship between serum miR-574-5p expression and clinical pathological characteristics in patients with breast cancer
下载PDF
导出
摘要 目的探讨微小RNA-574-5p(miR-574-5p)在乳腺癌患者血清中的水平及与临床病理特征的关系。方法选取2014年12月至2015年9月期间60例乳腺癌患者和60例乳腺纤维腺瘤患者作为研究对象,选择于同期在本院健康检查的60例健康女性作为健康对照组。采用实时荧光定量PCR(qPCR)检测入组对象血清miR-574-5p水平。结果经RT-PCR检测,乳腺癌组血清miR-574-5p水平为55.26±6.71,纤维瘤组血清miR-574-5p水平为14.21±4.11,健康对照组血清miR-574-5p水平为3.39±1.02,乳腺癌组miR-574-5p水平高于纤维腺瘤组和健康对照组,差异有统计学意义(F=68.17,P<0.05),纤维腺瘤组miR-574-5p水平高于健康对照组,差异有统计学意义(t=21.08,P<0.05)。随着患者病理分期的增加、肿瘤体积的增加、分化程度的降低,乳腺癌组血清miR-574-5p水平呈升高趋势,伴淋巴结转移的乳腺癌患者,血清miR-574-5p水平高于未出现淋巴结转移的乳腺癌患者(P<0.05)。手术后,乳腺癌患者血清miR-574-5p水平(46.19±6.15)明显低于治疗前(54.91±6.62),差异有统计学意义(t=16.72,P<0.05)。结论乳腺癌血清miR-574-5p水平高于良性乳腺病变及健康人群。血清miR-574-5p水平与乳腺癌的临床病理特征及预后密切相关。乳腺癌根治术可以抑制miR-574-5p的表达,改善患者病情。 Objective To study the relationship between serum miR-574-5p expression and clinical pathological characteristics in patients with breast cancer.Methods Totally 60 patients with breast cancer and 60 patients with fibroadenoma of breast were selected as the research subjects from December 2014 to September 2015,and 60 cases of healthy women in the hospital were selected as control group.The real-time fluorescence quantitative PCR(qPCR)was used to test serum miR-574-5p level.Results By RTPCR detection,serum miR-574-5p level of breast cancer was 55.26±6.71,serum levels miR-574-5p of fibroids group was 14.21±4.11,and level of miR-574-5p of healthy controls serum was 3.39±1.02.MiR-574-5p level of patients with breast cancer was higher than that of the fibroadenoma group and control group,and differences were statistically significant(F=68.17,P〈0.05),and miR-574-5p levels of fibroadenoma were higher than that of the healthy control group,and difference was statistically significant(t=21.08,P〈0.05).With the increase of pathological staging,the increase of tumor volume and decrease of degree of differentiation,serum miR-574-5p levels of breast cancer were increased.Serum miR-574-5p level of patients with breast cancer combined with lymph node metastasis was significantly higher than that of the patients without lymph node metastasis(P〈0.05).After surgery,serum miR-574-5p level of patients with the breast cancer(46.19±6.15)was lower than before(54.91±6.62),and the difference was statistically significant(t=16.72,P〈0.05).Conclusion Serum miR-574-5p level of breast cancer is higher than that of benign breast lesions and healthy people.Serum miR-574-5p level is closely related to the pathological characteristics and prognosis of breast cancer.Breast cancer radical operation can inhibit the expression of miR-574-5p and improve the patients′disease condition.
出处 《检验医学与临床》 CAS 2016年第21期3011-3013,共3页 Laboratory Medicine and Clinic
关键词 乳腺癌 miR-574-5p 病理特征 乳腺癌改良根治术 表达水平 breast cancer miR-574-5p pathological characteristics breast cancer modified radical expression level
  • 相关文献

参考文献14

二级参考文献55

  • 1AL-Hajj M, Wieha MS, Benito-Hernandez A, et al. Prospective iden- tification of tumorigenic breast cancer cells [ J ]. Proc Natl Acad Sci USA,2003,100(7) :3983-3988.
  • 2Knoop AS, Kudsen H, Balslev E, et al. Retrospetive analysis of topoisomerase II a amplifications and deletions as predictive mark- ers in primary breast cancer patients randomly assigned to cyclo- phosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group [ J ]. J Clin Oneol, 2005,23 (30) : 7483-7490.
  • 3Tanner M, Isola J, Wiklund T, et al. Topoisomerase 1I alpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER- 2/neu- amplified breast cancer: Scandinavian Breast Group Trial 9401 [J ]. J Clin Oncol, 2006,24(16) : 2428-2436.
  • 4Harrison H, Farnie G, Howell SJ, et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor[J]. Can- cer Res,2010,70(2) :709-718.
  • 5Guo J, Zhou J, Ying X, et al. Effects of stealth liposomal daunorubi- cin plus tamoxifen on the breast cancer and stem ceils [J]. J Pharm Sci,2010,13(2) : 136-151.
  • 6Sheridan C, Kishimoto H, Fuchs RK, et al. CD44~/CD24- breast can- cer cells exhibit enhanced invasive properties : an early step neces- sary for metastasis [ J ]. Breast Cancer Res, 2006,8 (5) : R59.
  • 7Sayed D, Abdellatif M. MicroRNAs in development and Physiol Rev, 2011,91 (3) : 827-887.
  • 8Carthew RW, Sontheimer EJ. Origins and mechanisms and siRNAs[J ]. Cell, 2009,136(4) : 642-655. disease[J] of miRNAs.
  • 9Shimono Y, Zabala M, Cho RW, et al. Downregulation of miRNA- 200c links breast cancer stem cells with normal stem cells [J]. Cell, 2009,138(3) :592-603.
  • 10Iliopoulos D, Lindahl-Allen M, Polytarchou C, et al. Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression re- quired for the formation and maintenance of cancer stem ceils [J]. Mol Ce11,2010,39(5) :761-772.

共引文献522

同被引文献50

引证文献5

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部